CORT
Corcept Therapeutics IncorporatedNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.46B
P/E Ratio
172.06
EPS
$0.35
Beta
0.35
52W High
$91.00
52W Low
$28.66
50-Day MA
$45.35
200-Day MA
$59.60
Dividend Yield
—
Profit Margin
6.16%
Forward P/E
75.19
PEG Ratio
0.81
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Fundamentals
| Revenue (TTM) | $769.10M |
| Gross Profit (TTM) | $755.64M |
| EBITDA | $-6.93M |
| Operating Margin | -30.10% |
| Return on Equity | 7.17% |
| Return on Assets | -0.62% |
| Revenue/Share (TTM) | $7.40 |
| Book Value | $5.94 |
| Price-to-Book | 10.04 |
| Price-to-Sales (TTM) | 8.41 |
| EV/Revenue | 7.9 |
| EV/EBITDA | 99.13 |
| Quarterly Earnings Growth (YoY) | -21.60% |
| Quarterly Revenue Growth (YoY) | 4.90% |
| Shares Outstanding | $107.35M |
| Float | $88.98M |
| % Insiders | 11.54% |
| % Institutions | 75.68% |
Historical Volatility
HV 10-Day
66.72%
HV 20-Day
58.42%
HV 30-Day
52.57%
HV 60-Day
59.29%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($79.00 target)
1
Strong Buy3
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026